Literature DB >> 18198245

Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis.

David A Zisman1, Arun S Karlamangla, Steven M Kawut, Oksana A Shlobin, Rajeev Saggar, David J Ross, Marvin I Schwarz, John A Belperio, Abbas Ardehali, Joseph P Lynch, Steven D Nathan.   

Abstract

BACKGROUND: We have developed a method to screen for pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients, based on a formula to predict mean pulmonary artery pressure (MPAP) from standard lung function measurements. The objective of this study was to validate this method in a separate group of IPF patients.
METHODS: Cross-sectional study of 60 IPF patients from two institutions. The accuracy of the MPAP estimation was assessed by examining the correlation between the predicted and measured MPAPs and the magnitude of the estimation error. The discriminatory ability of the method for PH was assessed using the area under the receiver operating characteristic curve (AUC).
RESULTS: There was strong correlation in the expected direction between the predicted and measured MPAPs (r = 0.72; p < 0.0001). The estimated MPAP was within 5 mm Hg of the measured MPAP 72% of the time. The AUC for predicting PH was 0.85, and did not differ by institution. A formula-predicted MPAP > 21 mm Hg was associated with a sensitivity, specificity, positive predictive value, and negative predictive value of 95%, 58%, 51%, and 96%, respectively, for PH defined as MPAP from right-heart catheterization > 25 mm Hg.
CONCLUSIONS: A prediction formula for MPAP using standard lung function measurements can be used to screen for PH in IPF patients.

Entities:  

Mesh:

Year:  2008        PMID: 18198245      PMCID: PMC2655111          DOI: 10.1378/chest.07-2488

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  25 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history.

Authors:  A Miller; J C Thornton; R Warshaw; H Anderson; A S Teirstein; I J Selikoff
Journal:  Am Rev Respir Dis       Date:  1983-03

3.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

4.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

5.  Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.

Authors:  Hanno H Leuchte; Claus Neurohr; Rainer Baumgartner; Michael Holzapfel; Wolfgang Giehrl; Michael Vogeser; Jürgen Behr
Journal:  Am J Respir Crit Care Med       Date:  2004-04-15       Impact factor: 21.405

Review 6.  Pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Nina M Patel; David J Lederer; Alain C Borczuk; Steven M Kawut
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

7.  Reference spirometric values using techniques and equipment that meet ATS recommendations.

Authors:  R O Crapo; A H Morris; R M Gardner
Journal:  Am Rev Respir Dis       Date:  1981-06

8.  External validation is necessary in prediction research: a clinical example.

Authors:  S E Bleeker; H A Moll; E W Steyerberg; A R T Donders; G Derksen-Lubsen; D E Grobbee; K G M Moons
Journal:  J Clin Epidemiol       Date:  2003-09       Impact factor: 6.437

9.  Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases.

Authors:  E Weitzenblum; M Ehrhart; J Rasaholinjanahary; C Hirth
Journal:  Respiration       Date:  1983       Impact factor: 3.580

10.  Standardized single breath normal values for carbon monoxide diffusing capacity.

Authors:  R O Crapo; A H Morris
Journal:  Am Rev Respir Dis       Date:  1981-02
View more
  11 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

2.  Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Authors:  D Papakosta; G Pitsiou; Z Daniil; M Dimadi; E Stagaki; A Rapti; K Antoniou; A Tzouvelekis; T Kontakiotis; S Tryfon; V Polychronopoulos; D Bouros
Journal:  Lung       Date:  2011-06-11       Impact factor: 2.584

3.  Improving on the diagnostic characteristics of echocardiography for pulmonary hypertension.

Authors:  Kathleen Broderick-Forsgren; Clemontina A Davenport; Joseph A Sivak; Charles William Hargett; Michael C Foster; Andrew Monteagudo; Alicia Armour; Sudarshan Rajagopal; Kristine Arges; Eric J Velazquez; Zainab Samad
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-24       Impact factor: 2.357

4.  Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Amy L Olson; Oksana A Shlobin; Shahzad Ahmad; Kevin K Brown; Steven D Nathan
Journal:  Respirology       Date:  2011-04       Impact factor: 6.424

5.  Evaluation of recently validated non- invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients.

Authors:  Maha K Ghanem; Hoda A Makhlouf; Gamal R Agmy; Hisham M K Imam; Doaa A Fouad
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

6.  Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli
Journal:  Respir Med       Date:  2016-06-02       Impact factor: 3.415

7.  Novel computed tomographic chest metrics to detect pulmonary hypertension.

Authors:  Andrew L Chan; Maya M Juarez; David K Shelton; Taylor MacDonald; Chin-Shang Li; Tzu-Chun Lin; Timothy E Albertson
Journal:  BMC Med Imaging       Date:  2011-03-29       Impact factor: 1.930

Review 8.  Managing comorbidities in idiopathic pulmonary fibrosis.

Authors:  Blair G Fulton; Christopher J Ryerson
Journal:  Int J Gen Med       Date:  2015-09-22

Review 9.  Therapeutic Approach to Adult Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Mary E Strek
Journal:  Chest       Date:  2016-08-10       Impact factor: 9.410

10.  Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?

Authors:  Małgorzata Sobiecka; Katarzyna Lewandowska; Jarosław Kober; Monika Franczuk; Agnieszka Skoczylas; Witold Tomkowski; Jan Kuś; Monika Szturmowicz
Journal:  Lung       Date:  2020-03-23       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.